GlassScriptPhysician profile
Amy S Clinton
NPI 1992962427
$6,826.52
in general payments reported to CMS, 2019-2025
47 companies · $1,532 in 2025
The $1,532 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $121 · 2022: $1,114 · 2023: $1,432 · 2024: $2,627 · 2025: $1,532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,312 · Long Term Medical Supply Or Device Loan: $1,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,311.79 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,823.46 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $418.75 | 2022-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $398.80 | 2022-2025 | Opdivo, Pomalyst, Opdualag |
| Eisai INC. | $375.82 | 2022-2025 | |
| Daiichi Sankyo INC. | $315.90 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Janssen Biotech, INC. | $290.33 | 2022-2025 | Imbruvica, Darzalex, Tecvayli |
| Celgene Corporation | $274.28 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Amgen INC. | $272.85 | 2022-2023 | Lumakras |
| Lilly USA, LLC | $240.84 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| Pfizer INC. | $225.61 | 2022-2025 | |
| Gilead Sciences, INC. | $201.62 | 2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $190.02 | 2022-2025 | Calquence, Enhertu, Tagrisso |
| Pharmacyclics LLC, An Abbvie Company | $142.81 | 2022-2023 | Imbruvica |
| Regeneron Healthcare Solutions, INC. | $136.03 | 2022-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $126.45 | 2022-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $118.39 | 2022-2024 | Alunbrig, Ninlaro |
| Abbvie INC. | $115.89 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $112.96 | 2022-2024 | Xpovio |
| Immunocore Limited | $99.68 | 2024 | Kimmtrak |
| Stemline Therapeutics INC. | $86.75 | 2023-2025 | Orserdu |
| Genentech USA, INC. | $82.45 | 2022-2025 | Polivy, Lunsumio, Columvi |
| Taiho Oncology, INC. | $66.76 | 2022-2025 | |
| Seagen INC. | $63.98 | 2022-2023 | Tukysa, Adcetris |
| Array Biopharma INC | $54.60 | 2022-2025 | Mektovi, Braftovi, Tukysa |
| Genzyme Corporation | $50.35 | 2022-2025 | |
| Astellas Pharma US INC | $50.02 | 2022-2025 | Xtandi, Padcev |
| Endo USA, INC. | $39.28 | 2025 | Xiaflex, Aveed |
| Glaxosmithkline, LLC. | $33.83 | 2025 | Blenrep, Zejula, Jemperli |
| Edwards Lifesciences Corporation | $33.13 | 2025 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $31.18 | 2021 | |
| Kyowa Kirin, INC. | $30.58 | 2023-2024 | Poteligeo |
| Sobi, INC | $30.02 | 2024 | |
| Urogen Pharma, INC. | $28.90 | 2025 | |
| Geron Corporation | $25.26 | 2025 | Rytelo |
| Beigene USA, INC. | $24.78 | 2025 | Brukinsa |
| Abbott Laboratories | $23.66 | 2021 | |
| Immunogen, INC. | $22.53 | 2023 | Elahere |
| Morphosys, US INC. | $22.39 | 2021 | |
| Kite Pharma, INC. | $18.63 | 2023 | |
| Alexion Pharmaceuticals, INC. | $18.21 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.33 | 2022 | |
| Servier Pharmaceuticals LLC | $16.85 | 2025 | |
| Aveo Pharmaceuticals, INC. | $16.64 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.91 | 2022 | |
| G1 Therapeutics, INC. | $15.62 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.46 | 2023 | Xarelto |
| Emd Serono, INC. | $12.93 | 2023 | Tepmetko |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Clinton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.